Zacks: Analysts Set $10.50 Target Price for ContraVir Pharmaceuticals Inc (NYSE:HEPA)

ContraVir Pharmaceuticals Inc (NYSE:HEPA) has earned an average broker rating score of 1.67 (Buy) from the three brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company. ContraVir Pharmaceuticals’ rating score has improved by 44.3% from three months ago as a result of a number of analysts’ ratings changes.

Brokerages have set a 12-month consensus target price of $10.50 for the company and are predicting that the company will post ($0.66) EPS for the current quarter, according to Zacks. Zacks has also given ContraVir Pharmaceuticals an industry rank of 50 out of 255 based on the ratings given to related companies.

Separately, Roth Capital reaffirmed a “buy” rating on shares of ContraVir Pharmaceuticals in a research report on Thursday, November 7th.

ContraVir Pharmaceuticals stock traded up $0.17 during mid-day trading on Tuesday, reaching $5.42. The company’s stock had a trading volume of 57,075 shares, compared to its average volume of 744,650. ContraVir Pharmaceuticals has a 12 month low of $2.00 and a 12 month high of $32.90.

An institutional investor recently bought a new position in ContraVir Pharmaceuticals stock. Virtu Financial LLC bought a new stake in ContraVir Pharmaceuticals Inc (NYSE:HEPA) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 18,060 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned approximately 0.52% of ContraVir Pharmaceuticals at the end of the most recent quarter.

ContraVir Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B.

Recommended Story: New Google Finance Tool and Screening Stocks

Get a free copy of the Zacks research report on ContraVir Pharmaceuticals (HEPA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.